Alzheimer’s disease (AD) is the most common cause of dementia, affecting millions of older adults worldwide and leading to progressive memory loss and cognitive decline1 . It is a complex neurodegenerative disorder caused by a combination of genetic, environmental, and lifestyle factors that damage brain cells over time2 . While there is no cure, current treatments can help manage symptoms and slow progression in some cases1 .
Key Theories and Causes
Alzheimer’s disease is marked by the gradual loss of neurons and synapses, especially in brain regions responsible for memory such as the hippocampus and entorhinal cortex. This neuronal loss leads to brain shrinkage and widespread cognitive impairment3 . Two main hypotheses explain the underlying causes of AD: the cholinergic hypothesis and the amyloid hypothesis.
Cholinergic Hypothesis
The cholinergic hypothesis was the first major theory developed to explain Alzheimer’s disease. It proposes that AD symptoms result from a deficiency of acetylcholine, a neurotransmitter essential for memory, learning, and attention4 . In AD, there is a marked reduction in cholinergic neurons, which impairs synaptic plasticity and cognitive function4 . This loss contributes to the characteristic memory decline seen in patients4 .
Current FDA-approved treatments for AD primarily include acetylcholinesterase inhibitors such as donepezil, rivastigmine, galantamine, and benzgalantamine. These drugs work by preventing the breakdown of acetylcholine, thereby increasing its levels in the brain and providing symptomatic relief4 5. However, these medications do not stop the underlying neurodegeneration and tend to lose effectiveness as the disease progresses4 5.
Amyloid Hypothesis
The amyloid hypothesis centers on the accumulation of beta-amyloid protein plaques in the brain as a key pathological hallmark of Alzheimer’s disease6 . These plaques form hardened clumps around neurons, disrupting cell function and triggering neurodegeneration7 . Alongside amyloid plaques, tau protein tangles develop inside neurons, further contributing to cell death7 .
Recent advances include FDA-approved immunotherapy drugs such as lecanemab and donanemab, which target beta-amyloid to reduce plaque buildup. Clinical trials have shown these drugs can slow cognitive decline in early AD stages and decrease amyloid levels in the brain5 8. However, side effects like amyloid-related imaging abnormalities (ARIA), involving fluid buildup or bleeding, require careful monitoring5 .
Research continues to explore additional mechanisms contributing to AD, including tau pathology, neuroinflammation, mitochondrial dysfunction, and vascular damage, highlighting the multifactorial nature of the disease3 698.
“Aducanumab’s efficacy as a treatment for cognitive dysfunction in Alzheimer’s disease cannot be conclusively proven due to divergent outcomes in clinical trials.”
— Michael Greicius10
Genetic Factors and Heredity
Genetics play a significant role in Alzheimer’s disease risk, though the influence varies by type and onset age. Early-onset familial Alzheimer’s disease, which occurs before age 65, is caused by rare inherited mutations in specific genes: amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) 111213. Individuals inheriting these deterministic gene variants have a very high likelihood of developing AD symptoms at a younger age12 .
Late-onset Alzheimer’s disease, the more common form appearing after age 65, has a complex genetic basis influenced by multiple genes and environmental factors14 13. The strongest genetic risk factor is the apolipoprotein E (APOE) gene, which exists in three common alleles: ε2, ε3, and ε415 12. The APOE ε4 allele increases the risk and lowers the age of onset, while APOE ε2 appears protective15 12.
- Having one APOE ε4 allele doubles or triples the risk of AD12 .
- Two ε4 alleles increase risk 8 to 12 times, but not everyone with ε4 develops AD12 16.
- APOE ε3 does not significantly affect risk12 .
Other genes linked to late-onset AD include ABCA7, CLU, CR1, PICALM, PLD3, TREM2, and SORL1, which influence processes like cholesterol metabolism, immune response, inflammation, and amyloid clearance14 13.
Genetic testing is generally recommended for individuals with a family history of early-onset AD but is less commonly used for late-onset cases due to limited predictive value17 12. Testing for APOE status may be important when considering anti-amyloid therapies, as ε4 carriers have a higher risk of side effects12 .
“Understanding how gene variants like APOE4 contribute to Alzheimer's disease progression may pave the way for novel treatment strategies. 10”
Alzheimer's Disease Demographics
Alzheimer’s disease predominantly affects older adults, with prevalence increasing sharply after age 6518 . Approximately 40% of people aged 85 and older have AD18 . Women represent nearly two-thirds of AD cases, largely because they tend to live longer than men rather than having a higher individual risk18 19. When adjusted for age, incidence rates between men and women are similar18 .
Ethnic disparities exist, with higher reported prevalence among Black and Hispanic populations. However, these differences are largely explained by socioeconomic and health factors rather than inherent genetic susceptibility18 . Recognizing these demographic patterns helps guide targeted research and healthcare planning to address disparities18 .
Primary Risk Factors
Alzheimer’s disease risk is influenced by a range of modifiable and non-modifiable factors. Age and genetics are the strongest non-modifiable risks, but several health and lifestyle factors also contribute significantly to disease development and progression20 1813.
Vascular (Blood Vessel) Conditions
Cardiovascular diseases such as hypertension, heart disease, and stroke are established risk factors for AD20 18. These conditions can cause cerebrovascular dysfunction, which promotes neuroinflammation and exacerbates Alzheimer’s pathology3 . Managing vascular health is crucial for reducing AD risk.
Metabolic Conditions
Metabolic disorders including diabetes, obesity, and high low-density lipoprotein (LDL) cholesterol increase the risk of developing Alzheimer’s disease20 18. Particularly, midlife obesity and elevated LDL cholesterol are linked to higher AD risk later in life20 . These conditions may contribute to brain inflammation and impaired metabolism.
Depression
Depressive symptoms are associated with an increased risk of Alzheimer’s disease, though it remains unclear whether depression is a prodromal symptom or an independent risk factor20 . The evidence on whether antidepressants reduce AD risk is inconclusive20 .
Social Isolation and Loneliness
“Impeding VCAM1, a protein that tethers circulating immune cells to blood vessel walls, enabled old mice to perform as well on memory and learning tests as young mice, according to a Stanford study.”
— Tony Wyss-Coray10
Social isolation (minimal social contact) and loneliness (subjective feeling of being alone) both increase the risk of cognitive decline and Alzheimer’s disease20 . Conversely, engagement in social activities offers protective benefits against cognitive deterioration20 .
“In a small safety trial based on preclinical work by a Stanford researcher, participants receiving blood plasma infusions from young donors showed some evidence of improvement.”
— Sharon Sha, Stanford University10
Additional factors linked to increased AD risk include:
- Traumatic brain injury (TBI) 13
- Heavy alcohol use13
- Smoking13
- Hearing loss13
- Air pollution exposure13
- Physical inactivity13
- Low mental engagement or cognitive inactivity13
Addressing these modifiable risks through lifestyle changes and medical management may help reduce the likelihood or delay the onset of Alzheimer’s disease.
Cardiovascular and metabolic health are key modifiable factors in Alzheimer’s risk. Controlling blood pressure, cholesterol, and diabetes can help protect brain function and slow cognitive decline. 1820
Summary and Key Takeaways
- Alzheimer’s disease is a progressive brain disorder characterized by memory loss and cognitive decline, primarily affecting older adults1 .
- The cholinergic hypothesis attributes symptoms to acetylcholine deficiency, while the amyloid hypothesis focuses on beta-amyloid plaque accumulation as central to AD pathology4 6.
- Genetics play a major role, especially mutations in APP, PSEN1, and PSEN2 for early-onset AD and the APOE ε4 allele for late-onset AD11 1512.
- Age is the strongest risk factor, with prevalence increasing sharply after 65 and reaching about 40% in those over 8518 .
- Modifiable risk factors include vascular and metabolic conditions, depression, social isolation, TBI, lifestyle habits, and environmental exposures20 1813.
- Current treatments mainly provide symptomatic relief and include cholinesterase inhibitors, memantine, and newer immunotherapies targeting amyloid plaques5 8.
- Ongoing research aims to develop disease-modifying therapies and better understand the complex mechanisms behind AD10 8.
